Helius Medical Technologies, Inc. Advances Bridge Loan

Helius Medical Technologies, Inc.

Healthcare & Pharmaceutical

Share Tweet

Helius Medical Technologies, Inc. Advances Bridge Loan

VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / June 3, 2014 - Helius Medical Technologies, Inc. ("Helius" or the "Company") announces that it has agreed to advance Neurohabilitation Corp. ("Neuro") a bridge loan in the amount of US $150,000 (the "Bridge Loan") in connection with the proposed acquisition announced in a previous news release dated May 30, 2014. The Bridge Loan is for a term of one year commencing on the date of advance and is payable in a lump sum at the end of the term. The Bridge Loan bears interest at a rate of 8% per annum.

For further information, please contact:

Marco Babini, Director

Helius Medical Technologies, Inc.

Telephone: 778-881-3232

Email: [email protected]

CAUTIONARY DISCLAIMER STATEMENT: The Company is a reporting issuer in the provinces of British Columbia and Alberta and not listed on any stock exchange. No stock exchange nor any regulation services provider accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

This news release contains forward-looking statements relating to the completion of the proposed Transaction, the release of escrowed proceeds, the use of proceeds from the Private Placement and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions to completion of the Transaction and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the proposed Transaction will be completed on the terms and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.